Lack of response suppression follows repeated ventral tegmental cannabinoid administration: An in vitro electrophysiological study

Neuroscience

Volumn 99, Issue 4, 2000, Pages 661-667

  Cheer, J F ^a   Marsden, C A ^a   Kendall, D A ^a   Mason, R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cannabinoids; DA; GABA; Interneuron; Reward; Ventral tegmental area

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; BICUCULLINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; RIMONABANT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; INTERNEURON; MALE; NERVE CONDUCTION; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; VENTRAL TEGMENTUM;

ACTION POTENTIALS; ANIMALS; BICUCULLINE; CANNABINOIDS; DOPAMINE; ELECTROPHYSIOLOGY; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; INTERNEURONS; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REWARD; TETRAHYDROCANNABINOL; VENTRAL TEGMENTAL AREA;

EID: 0034706069     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00241-4     Document Type: Article

References (37)

1. Bannon M.J., Roth R.H. Pharmacology of mesocortical dopamine neurons. Pharmac. Rev. 35:1983;53-68.
2. Chan P., Chan S., Yung W. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. NeuroReport. 9:1998;671-675.
3. Chiodo L.A. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci. Behav. Rev. 12:1988;49-91.
4. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmac. exp. Ther. 277:1996;586-594.
5. Cutler D., Mason R. A simple insert for the PDMI-2 microincubator offers mechanical stability for brain slice recording. J. Physiol., Lond. 497P:1996;P2-P3.
6. Davidson R.J., Irwin W. The functional neuroanatomy of emotion and affective style. TICS. 3:1999;11-21.
7. Deutch A. Y. and Bean A. J. (1995) Co-localization in dopamine neurons. In Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. E. and Kupfer D. J.). Raven, New York.
8. Diana M., Melis M., Muntoni A.L., Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc. natn. Acad. Sci. USA. 95:1998;10,269-10,273.
9. French E. Δ9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci. Lett. 226:1997;159-162.
10. Garcia D.E., Brown S., Hille B., Mackie K. Protein kinase C disrupts cannabinoid action by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci. 18:1998;2834-2841.
11. Gardner E.L., Vorel R.S. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 5:1998;502-533.
12. Gessa G.L., Melis M., Muntoni A., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmac. 341:1998;39-44.
13. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
14. Hernández M., Berrendero F., Suárez I., García-Gil L., Cebeira M., Mackie K., Ramos J.A., Fernández-Ruiz J. Cannabinoid CB1 receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res. 857:2000;57-65.
15. Hökfelt T., Skirboll L., Rehfeld J.F., Goldstein M., Markey K., Dann O. A sub-population of mesencephalic dopamine neurons projecting to limbic areas contain a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 5:1980;2093-2124.
16. Jin W., Brown S., Roche J., Hiseh C., Celver J., Kovoor A., Chavkin C., Mackie K. Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J. Neurosci. 19:1999;3773-3780.
17. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12:1992;483-488.
18. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
19. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16:1991;223-244.
20. Katona I., Beata S., Sik A., Kafalvi A., Sylveester Vizi E., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19:1999;4544-4558.
21. Kiyatkin E.A., Rebec G.V. Heterogeneity of ventral tegmental area neurons: single-unit recording and iontophoresis in awake, unrestrained rats. Neuroscience. 85:1998;1285-1309.
22. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid receptor. Eur. J. Pharmac. 334:1997;R1-R2.
23. Margulies J.E., Hammer R.P. Jr. Delta 9-tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur. J. Pharmac. 202:1991;373-378.
24. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
25. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. comp. Neurol. 327:1993;535-550.
26. Richardson J.D., Aanonsen L., Hargreaves K.M. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmac. 319:1997;R3-R4.
27. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Matinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere P., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Fedn Eur. biochem. Socs Lett. 350:1994;240-244.
28. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1:1998;132-137.
29. 35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59:1996;659-668.
30. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22:1999;521-527.
31. Steffensen S.C., Svingos A.L., Pickel V.M., Henriksen S.J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J. Neurosci. 18:1998;8003-8015.
32. Swanson L.W. The projection of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res. Bull. 9:1982;321-353.
33. Ton J.M.N.C., Gerhardt G.A., Friedemann M., Etgen A.M., Rose G.M., Sharpless N.S., Gardner E.L. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res. 451:1988;59-68.
34. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
35. Wang T., French E. L-Glutamate excitation of A10 dopamine neurons is preferentially mediated by activation of NMDA receptors: extra- and intracellular electrophysiological studies in brain slices. Brain Res. 627:1993;299-306.
36. White F.J. Synaptic regulation of mesocorticolimbic dopamine neurons. A. Rev. Neurosci. 19:1996;405-436.
37. 9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology. 39:2000;391-398.